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Summary
QUESTIONS UNDER STUDY: Since tumour burden con-
sumes substantial healthcare resources, precise cancer in-
cidence estimations are pivotal to define future needs of na-
tional healthcare. This study aimed to estimate incidence
and mortality rates of oesophageal, gastric, pancreatic, hep-
atic and colorectal cancers up to 2030 in Switzerland.
METHODS: Swiss Statistics provides national incidences
and mortality rates of various cancers, and models of future
developments of the Swiss population. Cancer incidences
and mortality rates from 1985 to 2009 were analysed to es-
timate trends and to predict incidence and mortality rates
up to 2029. Linear regressions and Joinpoint analyses were
performed to estimate the future trends of incidences and
mortality rates.
RESULTS: Crude incidences of oesophageal, pancreas,
liver and colorectal cancers have steadily increased since
1985, and will continue to increase. Gastric cancer inciden-
ce and mortality rates reveal an ongoing decrease. Pancre-
atic and liver cancer crude mortality rates will keep increas-
ing, whereas colorectal cancer mortality on the contrary
will fall. Mortality from oesophageal cancer will plateau or
minimally increase. If we consider European population-
standardised incidence rates, oesophageal, pancreatic and
colorectal cancer incidences are steady. Gastric cancers are
diminishing and liver cancers will follow an increasing
trend. Standardised mortality rates show a diminution for
all but liver cancer.
CONCLUSIONS: The oncological burden of gastrointest-
inal cancer will significantly increase in Switzerland during
the next two decades. The crude mortality rates globally
show an ongoing increase except for gastric and colorectal
cancers. Enlarged healthcare resources to take care of these
complex patient groups properly will be needed.
Key words: gastrointestinal cancers; healthcare
resources; cancer epidemiology
This paper was presented in part at the 100th Annual Congress of the
Swiss Surgical Society, June 12‒14, 2013, Bern, Switzerland.
Introduction
Many countries have achieved high standards of healthcare
for their populations. However, maintaining these care
levels is accompanied by a nearly uncontrolled increase of
costs that has required many countries to reorganise their
healthcare systems during recent years. Costs are thus the
most visible surrogate parameter reflecting ongoing irres-
istible improvements in modern medicine, as well as epi-
demiological phenomena like increasing population age,
and increase in cardiovascular diseases, diabetes mellitus
and obesity [1]. One should also keep in mind patients’
strong expectations for a long, healthy and active life in re-
turn for paying their national healthcare system.
In this setting, cancer belongs to the greatest burden on
healthcare in Western countries, as it is associated with a
considerable consumption of resources [2]. The fulminant
growing knowledge in various fields of basic research and
clinical medicine is leading towards personalised medicine
by using novel diagnostic and treatment options for indi-
vidual patients. For some cancer types, even curative treat-
ment options are available nowadays, while some other
cancers can be at least transformed into long-lasting, chron-
ic diseases with repeated treatments. Nonetheless, mod-
ern medicine struggles to develop effective treatments for
aggressive cancers, such as pancreatic adenocarcinoma,
where patients’ long-term survival is rare [3, 4].
Realistic estimations of future cancer incidences and mor-
tality rates are important parameters impacting on planning
and organisation of national healthcare [5]. Therefore, me-
ticulous data on cancer incidence and mortality over the
past years or, even better, decades, are required to establish
solid future trends. Unfortunately, national tumour regis-
tries are not yet established everywhere. Furthermore, a lot
of demographic items and epidemiological data (e.g., birth
rates, risk factors, population aging, or migration rates)
need to be known in order to be taken into account for cre-
ating reliable models of the future development of national
populations.
This study primarily aimed to evaluate the future national
burden of gastrointestinal cancers that Switzerland could
face in 2020–24 and 2025–29. Future crude incidence and
Swiss Medical Weekly · PDF of the online version · www.smw.ch Page 1 of 8
mortality rates of oesophageal, gastric, pancreatic, liver and
colorectal cancers were estimated.
Material and methods
Data sources and extraction
Swiss Statistics is the Federal Office of Statistics
(www.bfs.admin.ch) that has provided incidences and mor-
tality rates on various cancers since 1985 by summarising
the data of 16 regional tumour registries covering almost
the whole country [6]. Cancer incidences (new cases per
100 000 inhabitants, crude and standardised rates for
European population) and mortality rates (deaths per
100 000 inhabitants, crude and standardised rates for
European population) from 1985 to 2009 were analysed
to estimate trends of future incidence and mortality rates.
All Swiss data used for calculations were obtained from
the online database (STAT-TAB) of Swiss Statistics [6].
European-standardised incidences are based on the
European-standardised population of 2013.
Development of the Swiss population
Based on available national epidemiological data and es-
timates of external factors (i.e., migration phenomena,
Swiss foreign policy [socioeconomic trends and free move-
ment of persons in Europe], and demographic evolution
[population aging, birth and mortality rates]), Swiss Stat-
istics has constructed three different models of future de-
velopments of the Swiss population. The low hypothesis
model takes into account the lowest estimations of all the
above-mentioned parameters, whereas the high hypothesis
model takes into account the highest estimations. The av-
erage model between the low and high hypothesis models
is considered by Swiss Statistics as the most probable scen-
ario. These population models can also be obtained online
from Swiss Statistics [6]. The most probable scenario of
the future development of the Swiss population, as pro-
posed by Swiss Statistics, was used to calculate the new
cancer cases (incident cases) and the cancer-related deaths
for 2024 and 2029. Of note, crude rates were used since
they represent the real national cancer burden, and there-
fore, they fit better for future specific planning of health-
care resources.
According to Swiss Statistics’ proposed most probable
scenario, the Swiss population will be 8 524 627 inhabit-
ants in 2024 and 8 687 312 in 2029 comprising 4 200 991
males and 4 323 636 females in 2024, and 4 283 347 males
and 4 403 965 females in 2029. The male:female ratio will
be 0.97 in 2024 and 2029 in comparison with 0.98 in 2012.
Compared with 2012 (8 039 060 inhabitants), the popula-
tion will increase by 6% in 2024 and by 8.1% in 2029. The
median age range will be 55–59 years in 2024 and 60–64
years in 2029. Of the overall population, 22.4% will be
older than 65 in 2024 and 24.7% in 2029; in 2012, only
17.4% were among this age group.
Tumour types
Only primary cancers of the respective organs were in-
cluded in this current analysis; metastases from other or-
gans were excluded. Oesophageal cancers included squam-
ous cell carcinomas, adenocarcinomas and rare primaries
such as sarcomas. Gastric cancers included adenocarcino-
mas and rare primaries such as sarcoma or malignant
gastrointestinal stromal tumours (GIST). Tumours of the
gastroesophageal junction were classified as oesophageal
cancers. Pancreatic cancers encompassed ductal adenocar-
cinomas and all other types like cystadenocarcinomas or
malignant intraductal papillary and mucinous neoplasms
(IPMN). Liver cancers included hepatocellular carcinomas,
cholangiocarcinomas and rare primaries such as sarcomas.
Colorectal cancers mainly encompassed adenocarcinomas.
Methods of projections
Linear regressions and Joinpoint analyses [7] were per-
formed to estimate the future trends of incidences and mor-
tality rates. Linear regressions were calculated using
GraphPad Prism 5.0 for Mac OS X (GraphPad Software
Inc.). Joinpoint analyses allowed only one joinpoint (break-
point) and were performed by using Joinpoint Regression
Program, version 4.0.1 (January 2013), from the Statistical
Research and Applications Branch of the National Cancer
Institute [7]. Joinpoint projections were extrapolated from
the linear equation of the final segment. As Joinpoint is
not suitable for long-term predictions, mid-term time points
(2024 and 2029) were chosen.
International comparisons
Comparisons with other European and North American
countries were made. Relevant articles on gastrointestinal
cancer incidences and mortality rates were identified in
MEDLINE (through PubMed) by use of the appropriate
MeSH terms for the following search items: gastrointestin-
al cancer, epidemiology AND incidences AND mortality.
The search was limited to studies published between Janu-
ary 1980 and June 2013. Only articles published in English
were considered eligible [8].
Standardised rates for European populations were used for
international comparisons as appropriate. Otherwise, crude
incidence rates were preferred because they represent the
real national cancer burden.
Results
Crude incidence and mortality rates for Switzerland are
summarised graphically in figure 1. Joinpoint projections
of incidence and death rates for 2020–2024 and 2025–29
for all five cancers are reported in table 1.
Table 2 shows the Joinpoint projections of incidence rates
stratified by gender for 2020–24 and 2025–29 for all five
cancers (crude rates). It depicts that the incidence rates in
men followed and are predicted to follow similar trends as
the incidence rates in women for all the five cancers ex-
amined.
Oesophageal cancer
From 1985–89 to 2025–29, median annual crude rates of
oesophageal cancer incidences increased, according to the
two statistical methods used. According to the Joinpoint re-
gression, crude incidence rates will reach 8.4/100 000 in
2020–24 and 8.9/100 000 in 2025–29, whereas European-
standardised incidence rates will be 5.8/100 000 in
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Figure 1
Crude incidence (I, diamonds represent the figures extracted from
STAT-TAB) and mortality (M, asterisks represent the figures
extracted from STAT-TAB) rates (median per year per 100 000
inhabitants) from 1985‒89 to 2025‒2029 in Switzerland with linear
and Joinpoint regression models.
A Oesophageal cancer
B Gastric cancer
C Pancreatic cancer
D Liver cancer
E Colorectal cancer
2020–24 and 5.9/100 000 in 2025–29. The crude mortality
rates will rise slightly (linear method: from 5.4 in 1985–89
to 5.8/100 000 in 2025–29 and Joinpoint method: 6.7/
100 000 in 2025–29). The numbers of new oesophageal
cancer patients are predicted to be 716 and 773 in 2024 and
2029, respectively (317 in 1989), whereas the numbers of
oesophageal cancer deaths is predicted to be 546 and 582,
respectively (349 in 1989).
Gastric cancer
According to the two statistical methods, median annual
crude and European-standardised gastric cancer incidences
will strongly decrease until 2025–29. In 2020–24 the crude
incidence rate will be 5.7/100 000 (European-standardised:
4.7) and 4.2/100 000 (European-standardised: 3) in
2025–29 (Joinpoint method). The crude mortality rates will
also drastically diminish from 15.1 in 1985‒89 to 2.4/
100 000 in 2025–29 (Joinpoint method). The number of
new patients suffering from gastric cancer is estimated to
be 486 in 2024 and 361 in 2029 (1 106 in 1989), despite the
increased population. The numbers of deaths from gastric
cancer in 2024 and 2029 are estimated to be 307 and 209,
respectively (977 in 1989).
Pancreatic cancer
The linear and Joinpoint regressions predict that the crude
incidence rates of pancreatic cancer will increase in the
2025–29 period. According to the Joinpoint method the
median annual crude incidence rates will be 16.8/100 000
(standardised rate: 9.7) and 17.8/100 000 (standardised
rate: 9.7) in 2020–24 and 2025–29, respectively. The crude
mortality rate is predicted to increase (linear method: from
12.2 in 1985-89 to 13.9/100 000 in 2025–29 and Joinpoint
regression: 16.1/100 000 in 2025–29). The numbers of new
pancreatic cancer patients are predicted to be 1 434 in 2024
and 1 542 in 2029 (840 in 1989), while the number of
deaths related to pancreatic cancer is predicted to be 1 313
in 2024 and 1 399 in 2029 (789 in 1989).
Liver cancer
In 2025–29, the crude incidence rate of liver cancer pa-
tients is predicted to increase according to our two meth-
ods. The crude incidence is estimated to be 10.7/100 000
and 11.4/100 000 in 2020–24 and 2025–29, respectively
(Joinpoint analysis). According to the Joinpoint analysis,
the European-standardised incidence is estimated to be 7.5/
100 000 and 7.7/100 000 in 2020–24 and 2025–29, respect-
ively. Crude mortality rates are predicted to increase in
2020–24 (Joinpoint method: 10.5/100 000 and linear meth-
od: 9.8/100 000) and 2025–29 (Joinpoint method: 11.3/
100 000 and linear method: 10.4/100 000) periods. The
number of new liver cancer patients is estimated to be 913
in 2024 and 987 in 2029 (412 in 1989). Deaths due to liver
cancer are projected to be 895 and 982 in 2024 and 2029,
respectively (362 in 1989).
Colorectal cancer
Our two methods predict an increased crude incidence rate
of colorectal cancer in 2025–29. According to the Joinpoint
method crude incidence rates will reach 59.4/100 000
(European-standardised: 38) in 2020–24 and 61.1/100 000
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(European-standardised: 37.2) in 2025–29. On the con-
trary, crude mortality rates will significantly diminish in
2020–24 (from 28.8 in 1985‒89 to 18.3/100 000 according
to the Joinpoint regression) and 2025‒29 (17.2/100 000 ac-
cording to the Joinpoint regression). The number of new
patients suffering from colorectal cancers is predicted to be
5 066 and 5 304 in 2024 and 2029, respectively (3 194 in
1989). The number of deaths due to colorectal cancer is es-
timated to be 1 560 in 2024 and 1 494 in 2029 (1 863 in
1989).
Discussion
This study estimated future developments of gastrointest-
inal cancer incidences and mortality rates in Switzerland
up to 2030 and compared these findings with current in-
ternational data. While oesophageal, pancreatic, liver and
colorectal cancer incidences will significantly increase,
gastric cancer incidence is decreasing to a very low level.
Mortality rates of oesophageal, pancreatic and liver cancer
will remain either stable or slightly increase. In contrast,
gastric cancer and colorectal cancer mortality will signific-
antly decrease. The most common gastrointestinal malig-
nancy in Switzerland will be colorectal cancer, followed by
pancreatic, liver and oesophageal cancer.
Among the different tumour entities analysed, oesophageal
cancer will show an impressive increase in the number
of new cases (rise of 40% from 2005–09 to 2020–24), in
which males still predominate. As the Swiss population
substantially increases and gets older, the absolute number
of new cases per year will be 2.4 times higher in 2029 com-
pared with 1985. Since most oesophageal cancer patients
nowadays undergo multimodal treatment with radiochemo-
therapy and surgery, treatment costs will massively in-
crease. Similar findings have been reported in the United
Kingdom. Gatenby et al. estimated that the number of new
cases (adenocarcinomas and squamous cell carcinomas)
will rise by 40% for men from 2007 to 2020 [9].
In all European countries, gastric cancer mortalities have
shown an undiminished decline since 1980. For France, the
Netherlands, Sweden, Finland, Norway, Denmark and the
United Kingdom, it has been estimated that death rates will
further diminish by 66% from 2005 to 2030 [10]. Switzer-
land presented a similar diminution of gastric cancer mor-
tality rates for the past three decades. The 2000–04 mortal-
ity rates are predicted to diminish by 73% up to 2025–29
(8.8 to 2.4 per 100 000). As a consequence, management
of gastric cancer – regarding neither patient numbers nor
healthcare consumption – will represent an important issue
in the future. The only relevant question will be whether
the treatment of gastric cancer patients should not be cent-
ralised in a few centres to get a reasonable caseload guar-
anteeing high quality treatment.
Patient age is the single most important epidemiological
risk factor for pancreatic cancer. In order to get realistic
patient numbers for the planning of future healthcare re-
sources, only crude incidence rates should be used. It is an
illustrative example of how a malignant disease can be po-
tentially underestimated by reporting age-standardised in-
cidence rates. In Switzerland, the global age-standardised
incidence of pancreatic cancers has diminished from 10.7/
100 000 in 1985–89 to 9.7/100 000 in 2005–09. Neverthe-
less, according to our prediction based on crude inciden-
ce rates, in 2025–29 the number of new patients suffering
from pancreatic cancers will increase by 61% compared
with 2000–2004 (i.e., up to 1 542 patients) with a slight
Table 1: Joinpoint predicted incidence and death rates (median per year per 100’000 inhabitants) in Switzerland compared to 1985–89 and 2005–09 for all five tumour
entities.
Incidences (per 100 000) / Death rates (per 100 000)
1985–89 2005–09 2020–24 2025–29
Crude rates
Oesophageal cancer 4.9/5.4 6.8/5.6 8.4/6.4 8.9/6.7
Gastric cancer 17/15.2 10.4/7 5.7/3.6 4.2/2.4
Pancreatic cancer 12.9/12.2 14/13.4 16.8/15.4 17.8/16.2
Liver cancer 6.4/5.6 8.5/8.1 10.7/10.5 11.4/11.3
Colorectal cancer 48.9/28.8 54/21.4 59.4/18.3 61.1/17.2
Rates standardised to European population
Oesophageal cancer 4.6/5.1 5.4/4.3 5.8/4.2 5.9/4.2
Gastric cancer 14.4/12.3 7.7/4.9 4.7/1.1 3/0
Pancreatic cancer 10.7/10.1 9.7/9.2 9.7/9.2 9.7/9.2
Liver cancer 5.8/4.9 6.8/6.1 7.5/6.9 7.7/7.2
Colorectal cancer 41.6/23.3 40/14.6 38/9.5 37.2/7.8
Table 2: Incidence rates by gender from 1985 to 2009 and Joinpoint predicted incidence rates stratified by gender for 2020–24 and 2025–29 (median per year per 100 000
inhabitants) in Switzerland for all five tumour entities (crude rates).
Oesophageal Gastric Pancreatic Liver Colorectal
Men Women Men Women Men Women Men Women Men Women
1985–89 7.5 2.3 20.5 13.4 12.8 12.9 9.8 3.0 52.5 45.2
1990–94 8.1 2.7 17.9 11.8 12.1 11.7 9.7 3.0 53.7 45.0
1995–99 8.6 2.9 17.0 10.2 12.5 12.2 11.2 3.6 55.5 46.4
2000–04 10.0 3.2 14.6 8.7 13.2 13.2 13.1 4.1 59.8 48.0
2005–09 10.1 3.4 12.8 7.9 13.6 14.3 12.9 4.0 61.1 46.9
2020–24 12.6 4.1 6.9 4.3 15.6 17.9 16.0 4.9 70.3 48.7
2025–29 13.4 4.3 4.9 3.1 16.3 19.1 17.1 5.2 73.2 49.1
Original article Swiss Med Wkly. 2015;145:w14188
Swiss Medical Weekly · PDF of the online version · www.smw.ch Page 4 of 8
preponderance of male patients. Very similar findings have
been reported from Canada, where the incidence of pancre-
atic cancer has been stable for women from 1995 to 2002,
and has slightly diminished for men. However, the number
of pancreatic cancer cases is expected to more than double
in 2031: it is likely to be 5 619 patients as a result of a sub-
stantial increase of the population over 65 years of age [11].
Eheman et al. [12] predicted that in 2020 pancreatic cancer
will be the second cause of cancer death in the United
States, just behind lung cancer, which means it would jump
from the fourth to the second place. It is important to men-
tion that pancreatic cancer is the only gastrointestinal can-
cer that has an increase of both death rate and incidence.
The number of US people suffering from pancreatic cancer
is predicted to double by 2030 increasing to 62 000 people
[13]. Pancreatic cancer has become the fourth most fre-
quent cause of cancer death in both sexes in the European
Union (world-adjusted mortality rate 6.6/100 000 in 2013)
[14]. Our prediction model for Switzerland estimates that
in 2025‒29, pancreatic cancer could be the leading cause of
gastrointestinal cancer-related deaths.
Whereas worldwide liver cancer incidences will probably
remain stable in the forthcoming years, according to Bray
et al. [5], incidences in Switzerland will slightly increase
in the near future (from 6.8 per 100 000 inhabitants to 7.5
in 2020–24 and 7.7 in 2025–29 for the Joinpoint analysis).
Of note, once a successful treatment of hepatitis C is avail-
able, liver cancer incidences will decrease with a latency
of several years owing to the diminution of hepatocellu-
lar carcinomas [15]. In Switzerland, the peak of hepatit-
is C has been predicted to be in 2030, because presently
around 50% of the cases are estimated to be undiagnosed.
After reaching the incidence peak of the disease, a 20-year
latency will be seen before a diminution of hepatocellular
carcinomas will appear [16].
Regarding the liver cancer predictions (hepatocellular car-
cinomas, cholangiocarcinomas and other rare primaries),
an important point should be mentioned. Once the hepatitis
C incidence has decreased, the number of non-alcoholic
fatty liver disease (NAFLD) diagnoses will probably rise.
As NAFLD has been proven to be a risk factor for hepato-
cellular carcinoma, projections of future liver cancer incid-
ence are therefore very difficult [17].
Currently, Ireland has one of the highest rates of colon
cancer mortality in Europe (standardised rate: 16.2 per
100 000 for the 2003–07 period). However, the future trend
is toward a decline of this mortality rate (14 per 100 000 for
2013–17) due to screening programmes and public health
promotion [18, 19]. In Spain, colorectal cancer crude mor-
tality is likely to increase to 30.5/100 000 in 2015–19.
Mortality will slightly increase among men, and level off
among women [20]. In the USA, the population over 50
years of age represented 26% of the entire population in
1992 and will represent 36% in 2050. The consequence
will be a doubling of colorectal cancer admissions if the in-
cidence rates remain the same as today [21]. The colorectal
standardised mortality rate in Switzerland was 14.6 per
100 000 in 2005–09. The mortality will also diminish in
the future (prediction of a mortality rate of 9.5/100 000 in
2020–24 according to the Joinpoint regression).
In the Aragon province of Spain, colorectal cancer incid-
ence will rise gradually reaching 39/100 000 in 2022. The
incidence will particularly increase in men and slightly
decrease in women [22]. Predictions of Swiss colorectal
cancer incidences show a slight decrease for future years.
Indeed, the European population-adjusted incidence could
drop to 38 per 100 000 in 2020–24 compared to 41.7 in
1995–99. Switzerland will face a substantial increase of the
population aged over 50 years (from 32% of the population
in 1992 to 47.7% in 2050). The total number of colorectal
cancer cases will therefore increase in upcoming years.
Epidemiological data need to be interpreted cautiously. All
projections hypothesise that the same rate of cancer de-
tection will apply for the forthcoming years. However, in-
crease of incidences among some gastrointestinal cancers
can be a result of recent improvements of screening or dia-
gnostic methods. Moreover, the projection method should
be chosen according to the natural history of the cancer,
based on epidemiology. In this study, we decided to choose
two methods in order to have different variants. Regarding
the Joinpoint method used for extrapolation, it was as-
sumed that in the upcoming 10 to 15 years there will be
no important events that would induce significant changes
in the trajectory of the incidence rates. If this latter as-
sertion was false, the precision of the Joinpoint extrapol-
ations would decrease. Higher population age, increasing
obesity and diabetes mellitus rates, as well as behavioural
changes (e.g. smoking habits among women) are com-
monly observed in many Western countries. Changes in
cancer risk factors will definitely influence future cancer
epidemiology. In addition, migration phenomena impact
importantly on national populations. As migration is often
driven by economic reasons and the prospect of a better
life, rich countries encounter an increase of their national
population even though birth rates of the native population
are low; while poorer countries are at risk of younger
people leaving. The constant improvement of diagnostic
tools and cancer treatments is also an element to take into
account when analysing the future cancer burden. In addi-
tion to all these aspects, changes of gastrointestinal cancer
incidences are also possibly related to genetic and epigen-
etic variations between different populations.
Switzerland is classified as a high-income country and sev-
eral papers have shown that cancer epidemiology in
Switzerland is similar to some other Western and Northern
European countries [23–26]. Moreover, the majority of the
international comparisons of future cancer burden predic-
tions made between Switzerland and other European and
North American countries showed similar results [9–11,
14]. Data presented in this study can therefore be generalis-
able, or at least extrapolated, to countries with similar can-
cer epidemiology and comparable population demographic
evolution.
In conclusion, oesophageal, pancreatic, hepatic and
colorectal malignancies will represent an increasing
gastrointestinal cancer burden in Switzerland. Their nation-
al incidences are well in line with the findings in most
European and North American countries. Only gastric can-
cer will become a rare disease by the mid-21st century.
Since centralisation of complex surgery is an ongoing pro-
cess, future multidisciplinary cancer centres will require
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substantial resources in order to maintain a high treatment
quality.
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Figure 1
Crude incidence (I, diamonds represent the figures extracted from STAT-TAB) and mortality (M, asterisks represent the figures extracted from
STAT-TAB) rates (median per year per 100 000 inhabitants) from 1985‒89 to 2025‒2029 in Switzerland with linear and Joinpoint regression
models.
A Oesophageal cancer
B Gastric cancer
C Pancreatic cancer
D Liver cancer
E Colorectal cancer
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